Immun thrombocytopenic purpura in children with therapy modalities
Abstract number: PP-MO-073
Aydogan1 G., Celik1 M., Tugcu1 D., Salcioglu1 Z., Akici1 F., Kiyak1 A., Akcay1 A., Canpolat1 N., Sen1 H.
11Pediatric Hematology-Oncology, Bakirkoy Maternity and Children Training and Research Hospital, Istanbul, Turkey
How-to-cite Aydogan G, Celik M, Tugcu D, Salcioglu Z, Akici F, Kiyak A, Akcay A, Canpolat N, Sen H. Immun thrombocytopenic purpura in children with therapy modalities. Journal of Thrombosis and Haemostasis 2009; Volume 7, Supplement 2: Abstract PP-MO-073
We aimed to evaluate clinical course, treatment modalities and results in 60 pediatric Immun Thrombocytopenic Purpura (ITP) patients between November 2006- May 2008, prospectively. The mean age at presentation was 80.43 ± 44 months. Male/female ratio was 1.22. (33 male, 55%, 27 female, 45%). A history of preceeding infection before 4 weeks at presentation was obtained in 48% patients. There were upper tract infection in 23 patients (38%), smallpox in 2 patients (3%), rubeola in 1 patient (1.6%), hepatitis A in 1 (1.6%), mumps in 1 (1.6%), parvovirus B19 in 1 (1.6%). The mean presenting platelet count at diagnosis was lower than 20000/mm3 in all patients. Metil prednisolone was used in 20 patients (2 mg/kg/day,in divided 3 doses, max 60 mg/day, 4–6 weeks), intravenous immunoglobuline (IVIG) in 20 patients (0.4 g/kg/day, 5 consecutive days) and anti-D immunoglobuline in 20 patients (50 μg/kg/day). There was no statistical differences in response to therapy and progress to chronic form of ITP in these three groups. Response to therapy was 70% with steroid, 80% with IVIG, 65% with anti-D. There weren't any significant differences between recovery times between three groups. But thrombocyte count was significantly low in steroid group at day seven. Also decrease in hemoglobin level was detected in anti-D group but there was no need any therapy and recover spontaneously. Chronic ITP was observed in seven patients with steroid therapy (35%), in five patients with IVIG therapy (25%), in eight patients with anti-D therapy (40%).
Conclusion: Analysis of our patients demonstrated that there were no statistically significant differences in the effects of various treatment modalities. Anti-D therapy can be used as a treatment choice in nonsplenectomised, Rh positive, pediatric ITP patients. But there is a need studies with large series and long time follow-up to assess the efectiveness of therapies.
Disclosure of interest: none declared.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number
| Back to top